A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Study on the Efficacy and Safety of Debio 025 Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alisporivir (Primary) ; Peginterferon alfa-2a; Ribavirin
Indications Hepatitis C
Focus Therapeutic Use
Sponsors Debiopharm Group

Most Recent Events

07 Aug 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
23 Jun 2012 Company added in the association field as reported by EudraCT.
21 Apr 2012 European Clinical Trials Database reports trial status as recruting in France and Spain; planned patient number is 272.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight